Regeneron Pharmaceuticals, Inc. (REGN) Given Average Rating of “Hold” by Analysts
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been assigned a consensus recommendation of “Hold” from the twenty-nine research firms that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, thirteen have given a hold recommendation, twelve have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $492.95.
Several equities analysts recently issued reports on the company. J P Morgan Chase & Co reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 15th. Robert W. Baird downgraded Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price target for the company. in a research report on Tuesday, August 8th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $472.00 price target (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 price target for the company in a research report on Wednesday, August 9th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $580.00 price target (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th.
In other Regeneron Pharmaceuticals news, SVP Michael S. Aberman sold 2,269 shares of the stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $532.42, for a total transaction of $1,208,060.98. Following the transaction, the senior vice president now owns 9,193 shares in the company, valued at approximately $4,894,537.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Robert E. Landry sold 189 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the transaction, the chief financial officer now owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. Insiders have sold a total of 99,543 shares of company stock worth $47,831,369 in the last quarter. Company insiders own 10.40% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the business. Intl Fcstone Inc. bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $346,000. Lord Abbett & CO. LLC bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $51,931,000. Toronto Dominion Bank increased its position in Regeneron Pharmaceuticals by 25.8% during the 2nd quarter. Toronto Dominion Bank now owns 25,835 shares of the biopharmaceutical company’s stock worth $12,686,000 after buying an additional 5,295 shares during the period. WINTON GROUP Ltd bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $713,000. Finally, Public Employees Retirement System of Ohio increased its position in Regeneron Pharmaceuticals by 1.6% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 54,288 shares of the biopharmaceutical company’s stock worth $26,663,000 after buying an additional 867 shares during the period. Hedge funds and other institutional investors own 67.96% of the company’s stock.
Regeneron Pharmaceuticals (NASDAQ REGN) traded down 1.77% during mid-day trading on Friday, hitting $433.45. 1,002,422 shares of the company traded hands. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $543.55. The company has a market capitalization of $45.96 billion, a price-to-earnings ratio of 43.48 and a beta of 1.65. The company’s 50-day moving average price is $472.80 and its 200 day moving average price is $445.37.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The business had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same period in the previous year, the firm earned $2.82 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals will post $14.90 earnings per share for the current fiscal year.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.